Partnerships

The supplier will add Allied Laboratories and AR Brown to its list of global partners.

Baxter announces that it will partner with Mayo Clinic and Velocity Pharmaceutical to form Vitesse Biologics, a Baxalta-managed company focused on immunology, hematology, and oncology.

Visterra announces partnership with A*STAR to develop VIS513, a monoclonal antibody for the treatment of dengue fever.

MaxCyte announces a strategic partnership with Johns Hopkins University to develop CAR T-Cell therapies for cancer.

MedImmune will provide funds and access to monoclonal antibodies to seven postdoctoral associates for the creation of protein measurement and characterization tools.

The companies partnered to create more effective biopharmaceuticals through the exploitation of PASylation.

Pfenex announced that it entered into an agreement to partner with Hospira on the development and commercialization of PF582, a biosimilar candidate to Lucentis.

Mylan announced a partnership with Theravance Biopharma to develop and commercialize TD-4208, a novel investigational COPD treatment.

Under terms of the agreement, Zymeworks could earn up to $164 million per successful drug candidate.

Catalent announced that it would partner with Mitsubishi Gas Chemical Company, and its subsidiary MGC Pharma, to promote GPEx technology, a high-titer vector for stable mammalian cell lines.

Boehringer Ingelheim announced that it would partner with Vanderbilt University to research and develop Ras inhibitors for the treatment of cancers affected by Ras mutation.

The new partnership between NeoStem and Invetech focuses on the development of a closed processing system for cell-based therapy manufacturing.

Single-use components aid efficiency in automated personalized therapy manufacturing.

Xencor's technology focuses on the use of antibody and protein biotherapeutics to treat immune-related diseases.

The announcement calls attention to another partnership in the growing T-cell receptor engineering space.

GE Healthcare and Takeda Pharmaceutical Company announced an alliance to develop therapeutic drugs in the field of hepatic fibrosis to treat various liver diseases.

New research will focus on a superfamily of protein receptors linked to various diseases.

Celgene expands its oncology drug discovery and development portfolio through a new partnership with Sutro.

Asterias Biotherapeutics, Cancer Research UK, and Cancer Research Technology partner for clinical trial of immunotherapy vaccine for the treatment of lung cancer.

Eurobiomed and Biocom sign a cooperation agreement at the BIO International Convention.

BIO 2014 hosted more than 29,000 one-to-one partnering meetings.

Covance MarketPlace is designed to enable partnerships between the company's emerging biotechnology and established pharmaceutical clients.

Arecor and the Center for Process Innovation (CPI) Biologics are working on a project to enhance the compatibility of biologics with their containers.

NIH, 10 biopharmaceutical companies, and several nonprofit organizations form a partnership to develop new treatments earlier for Alzheimer's, type 2 diabetes, and autoimmune disorders.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.